Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
67%(2 trials)

Phase Distribution

Ph phase_4
1
25%
Ph phase_3
1
25%
Ph not_applicable
2
50%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)
N/ANon-phased studies
2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Other(1)

Detailed Status

Completed3
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 31 (25.0%)
Phase 41 (25.0%)
N/A2 (50.0%)

Trials by Status

unknown125%
completed375%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_3

Safety and Immunogenicity of Recombinant Hepatitis B Vaccine Sci-B-Vac® Compared to Engerix-B®

NCT04209400
completedphase_4

A Study to Qualify an In-house Reference Standard Batch of Sci-B-Vac™

NCT04179786
completednot_applicable

Hepatitis B Vaccine in Patients With Inflammatory Bowel Disease

NCT01531075
unknownnot_applicable

Efficiency of the Hepatitis B Sci-B-Vac Vaccine in HIV Positive Patients

NCT01437475

Clinical Trials (4)

Showing 4 of 4 trials
NCT04209400Phase 3

Safety and Immunogenicity of Recombinant Hepatitis B Vaccine Sci-B-Vac® Compared to Engerix-B®

Completed
NCT04179786Phase 4

A Study to Qualify an In-house Reference Standard Batch of Sci-B-Vac™

Completed
NCT01531075Not Applicable

Hepatitis B Vaccine in Patients With Inflammatory Bowel Disease

Completed
NCT01437475Not Applicable

Efficiency of the Hepatitis B Sci-B-Vac Vaccine in HIV Positive Patients

Unknown

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4